Assembly Biosciences (ASMB) Change in Receivables (2017 - 2026)
Assembly Biosciences (ASMB) posted quarterly Change in Receivables of -$523000.0 for Q1 2026, down 943.55% quarter-over-quarter from $62000.0 in Q4 2025.
Assembly Biosciences (ASMB) Change in Receivables (2017 - 2026) Analysis & Trends
Assembly Biosciences' Change in Receivables history runs 10 years deep, the most recent figure standing at -$523000.0 for Q1 2026.
- In Q1 2026, Change in Receivables changed N/A year-over-year to -$523000.0; the TTM figure through Mar 2026 stood at $451000.0 (up 1148.84% YoY), while the FY2025 annual figure was $974000.0, up 2365.12% from the prior year.
- Change in Receivables for Q1 2026 stood at -$523000.0, down from $62000.0 in the prior quarter.
- The five-year high for Change in Receivables was $912000.0 in Q3 2025, with the low at -$523000.0 in Q1 2026.
- The 5-year median for Change in Receivables is -$22000.0 (2022), against an average of $9583.3.
- The sharpest annual moves came in 2022 and 2023: Change in Receivables surged 118.31% in 2022, then tumbled 37400.0% in 2023.
- Assembly Biosciences' Change in Receivables stood at -$302000.0 in 2022, then soared by 114.24% to $43000.0 in 2023, then slumped by 200.0% to -$43000.0 in 2024, then jumped by 244.19% to $62000.0 in 2025, then plunged by 943.55% to -$523000.0 in 2026.
- Business Quant data shows ASMB's Change in Receivables at -$523000.0 in Q1 2026, $62000.0 in Q4 2025, and $912000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | 371,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 371,000.00 |
| Jun 30, 2026 | 371,000.00 |
| Mar 31, 2026 | -523,000.00 |
| Mar 31, 2026 | -523,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Sep 30, 2025 | 912,000.00 |
| Sep 30, 2025 | 912,000.00 |
| Jun 30, 2024 | -43,000.00 |
| Jun 30, 2024 | -43,000.00 |
| Dec 31, 2023 | 43,000.00 |
| Dec 31, 2023 | 43,000.00 |
| Sep 30, 2023 | -342,000.00 |
| Sep 30, 2023 | -342,000.00 |
| Jun 30, 2023 | -375,000.00 |
| Jun 30, 2023 | -375,000.00 |
| Mar 31, 2023 | -227,000.00 |
| Mar 31, 2023 | -227,000.00 |
| Dec 31, 2022 | -302,000.00 |
| Dec 31, 2022 | -302,000.00 |